Garcinol / cycD1/CCND1 Cancer Research Results

GAR, Garcinol: Click to Expand ⟱
Features:
Found in dried fruit rind of Garcinia Indica with anti-inflammatory, antioxidant, anticancer, and antibacterial properties
Garcinia Cambogia Extract.
"We conclude that patients who are T-cadherin-positive could especially benefit from a therapy with garcinol."

🔬1) NF-κB & AP-1 Suppression
Garcinol inhibits NF-κB and AP-1 transcriptional activity in multiple cancer cell systems, reducing pro-inflammatory and pro-survival gene expression.
📚 2) Epigenetic Regulation
Garcinol is one of the few natural products shown to inhibit p300/CBP histone acetyltransferases, shifting chromatin acetylation and influencing gene expression (differentiation, apoptosis, EMT). This is more specific than general “HDAC modulation.”
💀 3) Apoptosis
Studies report modulation of the Bcl-2 family and increased caspase activity, but this is often downstream of transcription/epigenetic changes, not a direct redox trigger.
🧬 4) Cell Cycle & Proliferation
Lower Cyclin D1, higher p21/p27, and G1/S arrest are common phenotypes.
🧭 5) Invasion & Angiogenesis
Garcinol reduces MMP-2/9 and angiogenic markers in multiple tumor cell assays.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB / AP-1 signaling NF-κB ↓; AP-1 ↓; downstream pro-survival/inflammatory outputs ↓ ↔ or anti-inflammatory modulation in immune cells R, G Pro-survival & inflammatory transcription suppression Garcinol is reported to inhibit NF-κB and AP-1 transcriptional activity, reducing inflammation and pro-growth signaling in multiple models.
2 Epigenetic regulation (HAT/HDAC modulation) Inhibition of p300/CBP histone acetyltransferase; altered acetylation patterns ↔ baseline epigenetic state R, G Gene regulatory reprogramming Garcinol directly inhibits histone acetyltransferases (especially p300/CBP), influencing chromatin state and gene expression linked to differentiation and proliferation.
3 Intrinsic apoptosis (mitochondrial / caspase-linked) ↑ Bax/Bak; ↓ Bcl-2/Bcl-xL; ↑ caspase-9/3 ↔ minimal activation in normal cells G Execution of apoptosis Often downstream of stress and survival pathway modulation; not as dominant as classic pro-oxidant molecules but consistent in many cell lines.
4 Cell-cycle checkpoints (p21/p27; Cyclin D1) Cell-cycle arrest (often G1/S); Cyclin D1 ↓ ↔ G Cytostasis Frequently reported as later phenotypic outcome tied to reduced proliferation.
5 Invasion / metastasis programs (MMPs / EMT) MMP-2/9 ↓; invasion/migration ↓; EMT markers ↓ ↔ G Anti-invasive phenotype Linked mechanistically to NF-κB/AP-1 and epigenetic changes influencing MMP expression and EMT regulators.
6 Angiogenesis signaling (VEGF & pro-angiogenic factors) VEGF ↓; pro-angiogenic markers ↓ ↔ G Anti-angiogenic support Sometimes measured in later in vivo or emulated assay systems; reflects downstream gene expression changes.
7 PI3K/AKT / survival kinases ↓ PI3K/AKT signaling (model-dependent) ↔ R, G Survival/growth suppression Modulation of survival kinases is reported in some systems but not a universal primary mechanism.
8 ROS / oxidative stress (context–dependent) ROS modulation (inconsistent across models) ↔ P, R, G Conditional stress modulation Some studies report mild ROS changes, but garcinol is not a strong pro-oxidant driver like BetA or curcumin in cancer cells.
9 Chemo-sensitization / combination relevance Enhanced sensitivity to chemotherapeutics (context) — G Combination leverage Combination effects are reported in selected cell lines/model systems; not universal.
10 Bioavailability constraint (oral exposure / formulation dependence) Systemic exposure often limited without enhanced delivery — — Translation constraint Poor native bioavailability is common across polyphenols/bzp molecules; formulations improve systemic exposure.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical-chemical effects; rapid signaling / kinase shifts)
  • R: 30 min–3 hr (acute stress-response and transcription signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
Scientific Papers found: Click to Expand⟱
826- GAR,    Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- vitro+vivo, HCC, HepG2 - vitro+vivo, Liver, HUH7
STAT3↓, TumCP↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, Mcl-1↓, survivin↓, VEGF↓, TumCCA↑, TumVol↓,
804- GAR,    Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest
- in-vitro, EC, HEC1B - in-vitro, EC, ISH
TumCP↓, TumCCA↑, P53↑, P21↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycB/CCNB1↓, p‑cJun↑,
798- GAR,    Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17β-estradiol
- in-vitro, BC, MCF-7
TumCP↓, TumCCA↑, Apoptosis↑, ac‑H3↑, ac‑H4∅, NF-kB↓, ac‑p65↑, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓,
801- GAR,  Cisplatin,    Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers
- in-vivo, HNSCC, NA
Apoptosis↑, cycD1/CCND1↓, Bcl-2↓, survivin↓, VEGF↓, TumCG↓, Ki-67↓, CD31↓,
802- GAR,    Garcinol acts as an antineoplastic agent in human gastric cancer by inhibiting the PI3K/AKT signaling pathway
- in-vitro, GC, HGC27
TumCP↓, TumCI↓, Apoptosis↑, PI3K/Akt↓, Akt↓, p‑mTOR↓, cycD1/CCND1↓, MMP2↓, MMP9↓, BAX↑, Bcl-2↓,
803- GAR,    Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↑, CDK6↑, P21↑, p27↑, ERK↓, MAPK↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

PI3K/Akt↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 2,   MAPK↓, 1,   Mcl-1↓, 1,   p27↑, 1,   survivin↓, 2,  

Transcription & Epigenetics ⓘ

p‑cJun↑, 1,   ac‑H3↑, 1,   ac‑H4∅, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 2,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 6,   CycD3↓, 1,   cycE/CCNE↑, 1,   P21↑, 2,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   p‑mTOR↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

CD31↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCP↓, 5,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   ac‑p65↑, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 38

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
6 Garcinol
1 Cisplatin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:83  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page